AU
AUPH.US Aurinia Pharmaceuticals Inc
- Market cap
- USD 2.11B
- P/E
- 6.9x
- P/B
- 3.30x
- ROE
- 21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AUPH.US undervalued?
Graham numberAUPH.US trades 0.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aurinia Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Aurinia Pharmaceuticals Inc yet.
Aurinia Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases…
Full company profileAurinia Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aurinia Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 173K | 420K | 463K | 318K | 50.1M | 45.6M | 134M | 176M | 235M | 283M | 326M |
| Gross Profit | 169K | 419K | -40.9M | 318K | 50.1M | 44.5M | 128M | 161M | 207M | 250M | 298M |
| Operating Income | -22.8M | -47.1M | -56.2M | -90.9M | -104M | -181M | -111M | -91.7M | -4.69M | 105M | 164M |
| EBITDA | -21.3M | -45.6M | -53.9M | -89.8M | -103M | -177M | -109M | -63.0M | 31.7M | 128M | 198M |
| Net Income | -23.3M | -70.8M | -64.1M | -88.4M | -103M | -181M | -108M | -78.0M | 5.75M | 287M | 138M |
| EPS | -0.66 | -0.92 | -0.76 | -0.95 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 | 1.02 |
| Balance Sheet | |||||||||||
| Total Assets | 57.0M | 190M | 146M | 324M | 464M | 543M | 471M | 548M | 551M | 752M | 826M |
| Total Liabilities | 21.0M | 24.1M | 33.3M | 25.7M | 55.9M | 64.3M | 65.4M | 170M | 173M | 170M | 168M |
| Shareholders' Equity | 36.0M | 166M | 113M | 299M | 408M | 479M | 405M | 378M | 377M | 581M | 658M |
| Cash & Short-term Investments | 39.6M | 173M | 126M | 306M | 398M | 466M | 389M | 350M | 358M | 398M | 487M |
| Total Debt | - | - | - | - | 8.41M | 8.74M | 8.09M | 97.6M | 79.4M | 74.8M | 58.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.7M | -41.2M | -51.6M | -63.6M | -69.9M | -158M | -79.5M | -33.5M | 44.4M | 136M | 175M |
| Capital Expenditure | 25.0K | 25.0K | 75.0K | 101K | 7.34M | 1.50M | 292K | 718K | 281K | 252K | 84.2K |
| Free Cash Flow | -18.7M | -41.2M | -51.7M | -63.7M | -77.2M | -159M | -79.8M | -34.2M | 44.1M | 135M | 175M |
| Ratios | |||||||||||
| ROE | -64.8% | -42.7% | -57.0% | -29.6% | -25.2% | -37.8% | -26.7% | -20.6% | 1.5% | 49.4% | 21.0% |
| ROA | -40.9% | -37.3% | -44.0% | -27.3% | -22.1% | -33.3% | -23.0% | -14.2% | 1.0% | 38.2% | 16.7% |
| Net Profit Margin | -13,465.3% | -16,855.2% | -13,848.8% | -27,794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% | 42.3% |
| Debt to Equity | - | - | - | - | 0.02x | 0.02x | 0.02x | 0.26x | 0.21x | 0.13x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aurinia Pharmaceuticals Inc dividends
Aurinia Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Oct 23, 2013.
Who owns Aurinia Pharmaceuticals Inc
- Insiders 6.81%
- Institutions 61.00%
- Public & others 32.19%
- Shares outstanding 134M
- Free float 130M
Top funds holding AUPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 3.01M | 2.24% | 0.00% | Oct 2026 |
| GS Glb Sm Cp CORE Eq Base Inc USD Snap | 1.63M | 1.21% | +7.81% | Aug 2026 |
| Fidelity Small Cap Index | 1.31M | 0.97% | +0.16% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.12M | 0.84% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 917K | 0.68% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 693K | 0.52% | +1.16% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 481K | 0.36% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 474K | 0.35% | +0.27% | Oct 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 400K | 0.30% | +23.86% | Jun 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 335K | 0.25% | +1,045.01% | Jul 2026 |
| Bridge Builder Small Cap Fund | 317K | 0.24% | +89.65% | Oct 2026 |
| Vanguard Health Care ETF | 314K | 0.23% | +0.11% | Sep 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 304K | 0.23% | +210.13% | Jul 2026 |
| Federated Hermes MDT Small Cap Growth IS | 291K | 0.22% | +260.98% | Sep 2026 |
| Schwab Small Cap Index | 289K | 0.22% | -0.48% | Sep 2026 |
| CREF Total Global Stock Account R3 | 264K | 0.20% | 0.00% | Aug 2026 |
| GS US Sm Cp CORE Eq Base Inc USD Snap | 262K | 0.20% | +1.10% | Aug 2026 |
| Principal US Small Cap ETF | 235K | 0.18% | +0.05% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 222K | 0.17% | -0.75% | Sep 2026 |
| Burney U.S. Factor Rotation ETF | 219K | 0.16% | 0.00% | Feb 2026 |
Top institutions holding AUPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 13.0M | 9.73% | +6.66% | Jun 2026 |
| BlackRock Inc | 8.19M | 6.11% | +4.43% | Jun 2026 |
| The Goldman Sachs Group Inc | 5.62M | 4.19% | +292.00% | Jun 2026 |
| NEA Management Company, LLC | 3.97M | 2.96% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 3.47M | 2.59% | +1.13% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 3.26M | 2.44% | -0.62% | Jun 2026 |
| State Street Corp | 2.59M | 1.93% | +2.47% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.31M | 1.72% | +3.39% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.04M | 1.53% | +9.04% | Jun 2026 |
| Geode Capital Management, LLC | 1.70M | 1.27% | +10.75% | Jun 2026 |
| Renaissance Technologies Corp | 1.55M | 1.16% | -6.96% | Jun 2026 |
| D. E. Shaw & Co LP | 1.41M | 1.05% | -10.46% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.36M | 1.01% | +8.17% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.23M | 0.92% | +12.24% | Jun 2026 |
| Jupiter Asset Management Limited | 1.09M | 0.82% | +36.23% | Jun 2026 |
| LSV Asset Management | 1.08M | 0.81% | +3.84% | Jun 2026 |
| Nomura Holdings Inc | 979K | 0.73% | +1.00% | Jun 2026 |
| AQR Capital Management LLC | 949K | 0.71% | -0.01% | Jun 2026 |
| Northern Trust Corp | 864K | 0.64% | +4.79% | Jun 2026 |
| Allianz Asset Management AG | 842K | 0.63% | 0.00% | Jun 2026 |
Aurinia Pharmaceuticals Inc company profile
- Company name
- Aurinia Pharmaceuticals Inc
- Ticker
- AUPH.US
- ISIN
- CA05156V1022
- Exchange
- USA Stocks
- Listed since
- Jan 26, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
- Phone
- 250 744 2487
- Website
- auriniapharma.com
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc management
7- Mr. Kevin C. TangChairman & CEO · born 1967
- Mr. Stephen P. RobertsonChief Legal Officer, Corporate Secretary & Chief Compliance Officer · born 1982
- Mr. Peter S. Greenleaf M.B.A.Consultant · born 1970
- Mr. Michael S. Hearne CPAChief Financial Officer · born 1963
- Mr. Ryan ColeChief Operating Officer · born 1987
- Mr. Thomas WeiChief Scientific Officer · born 1976
- Mr. Stewart M. KrollChief Development Officer · born 1959